Shinsuke Mizutani Selected Research

Bortezomib (Velcade)

1/2022	Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
1/2020	Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
1/2016	Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.
4/2015	Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy.
12/2014	Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
5/2012	Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.
11/2010	Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shinsuke Mizutani Research Topics

Disease

11	Multiple Myeloma 03/2022 - 11/2010
5	Hemorrhage 11/2020 - 08/2014
4	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2021 - 01/2014
4	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2018 - 01/2014
4	Chromosome Aberrations (Chromosome Abnormalities) 05/2017 - 05/2012
3	Neoplasms (Cancer) 03/2022 - 01/2011
3	Fever (Fevers) 01/2022 - 01/2014
3	Infections 01/2022 - 11/2020
3	Cognitive Dysfunction 10/2021 - 01/2020
2	Hypertension (High Blood Pressure) 01/2022 - 03/2016
2	Pneumonia (Pneumonitis) 01/2022 - 01/2018
2	Disease Progression 01/2022 - 12/2014
2	Lymphoma (Lymphomas) 01/2020 - 11/2012
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 07/2019 - 05/2018
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019 - 11/2012
2	Periodontal Diseases (Periodontal Disease) 03/2016 - 12/2015
2	Periodontitis 10/2014 - 12/2012
2	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2014 - 11/2012
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2014 - 11/2013
2	Disseminated Intravascular Coagulation 04/2013 - 01/2011
1	Frailty 03/2022
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 01/2022
1	Cough 01/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	COVID-19 01/2022
1	Pharyngitis (Sore Throat) 01/2022
1	Tooth Mobility 11/2021
1	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 11/2021
1	Alzheimer Disease (Alzheimer's Disease) 11/2021
1	Neuroinflammatory Diseases 11/2021
1	Memory Disorders (Memory Loss) 11/2021
1	Dementia (Dementias) 01/2021
1	Myeloid Sarcoma (Chloroma) 01/2021
1	Rupture 01/2021
1	Thromboembolism 11/2020
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2020
1	Malnutrition (Nutritional Deficiencies) 01/2020
1	Gangrene 01/2020
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/2019
1	Carcinogenesis 01/2019
1	Esophageal Neoplasms (Esophageal Cancer) 12/2018
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 01/2018
1	Testicular Neoplasms (Testicular Cancer) 01/2018

Drug/Important Bio-Agent (IBA)

7	Bortezomib (Velcade)FDA Link 01/2022 - 11/2010
5	Rituximab (Mabthera)FDA Link 07/2019 - 11/2012
4	Dexamethasone (Maxidex)FDA LinkGeneric 01/2022 - 05/2012
3	carfilzomibIBA 03/2022 - 01/2022
3	Lenalidomide (CC 5013)FDA Link 01/2022 - 01/2016
3	cyclopropapyrroloindoleIBA 11/2016 - 08/2014
2	Phosphotransferases (Kinase)IBA 03/2022 - 12/2012
2	Methotrexate (Mexate)FDA LinkGeneric 11/2021 - 01/2014
2	Azacitidine (5 Azacytidine)FDA Link 01/2021 - 01/2014
2	Prednisolone (Predate)FDA LinkGeneric 01/2020 - 01/2016
2	Bendamustine Hydrochloride FDA Link 07/2019 - 05/2018
2	Dacarbazine (DIC)FDA LinkGeneric 04/2013 - 01/2011
1	BI D1870IBA 03/2022
1	ipatasertibIBA 03/2022
1	eltrombopag FDA Link 01/2022
1	Interleukin-6 (Interleukin 6)IBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2022
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022
1	Inosine Triphosphate (ITP)IBA 01/2022
1	Neutralizing AntibodiesIBA 01/2022
1	Proteasome InhibitorsIBA 01/2022
1	Amyloid (Amyloid Fibrils)IBA 11/2021
1	iguratimodIBA 11/2021
1	Interleukin-10 (Interleukin 10)IBA 11/2021
1	Serine (L-Serine)FDA Link 11/2021
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2021
1	Proteins (Proteins, Gene)FDA Link 11/2021
1	Transforming Growth Factors (Transforming Growth Factor)IBA 11/2021
1	LipopolysaccharidesIBA 11/2021
1	postsynaptic density proteinsIBA 11/2021
1	Biomarkers (Surrogate Marker)IBA 10/2021
1	InflammasomesIBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	SynaptophysinIBA 01/2021
1	Cathepsin BIBA 01/2021
1	ORALIT (ORS)IBA 11/2020
1	Interleukin-2 (IL2)IBA 01/2020
1	Melphalan (Alkeran)FDA LinkGeneric 01/2020
1	AZD5153IBA 01/2019
1	AZD4320IBA 01/2019
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 12/2018
1	Benzethonium (Magic, Formula)IBA 12/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2018
1	Ganciclovir (Cytovene)FDA LinkGeneric 01/2018

Therapy/Procedure

15	Therapeutics 03/2022 - 04/2010
6	Drug Therapy (Chemotherapy) 01/2021 - 01/2011
2	Oral Hygiene (Dental Hygiene) 12/2018 - 12/2015
2	Oral Diagnosis (Oral Examination) 11/2016 - 02/2016
2	Stem Cell Transplantation 01/2014 - 10/2013
1	Drug Tapering 01/2022
1	Perioperative Period 11/2021
1	Hematopoietic Stem Cell Transplantation 01/2021
1	Tooth Extraction (Tooth Extractions) 11/2020
1	Heart-Assist Devices 11/2020
1	Kidney Transplantation 01/2020
1	Activities of Daily Living (ADL) 01/2020